Medical Pharmacology Chapter 35  Antibacterial Drugs

Section Table of Contents

Site Table of Contents

Previous Page

Next Page

  • Second Generation Cephalosporins:  Cefuroxime

     
    Oral Administration

     

    • Pharyngitis and Tonsillitis (Oral Cefuroxime Axetil)2,3,4

      • Cefuroxime axetil administration may be appropriate for treatment of mild-to-moderate strep throat (pharyngitis/tonsillitis) caused by Streptococcus pyogenes in patients ≥13 years old.

        • Cefuroxime is essentially a second-line option for strep throat in adolescents or adults who cannot take penicillins.

        • Cefuroxime may be used in children (certain age groups).5

    • Acute Otitis Media  (Oral Cefuroxime Axetil)

      • Treatment of acute otitis media in children (and adults) due to S. pneumoniae, H. influenzae, M. catarrhalis, or S. pyogenes (including β-lactamase producing strains of Haemophilus influenzae and Moraxella catarrhalis).2 

      • Treating acute otitis media is an important pediatric of cefuroxime due to its effectiveness against the major acute otitis media pathogens.6,7,8

        • If a child has an ear infection not responding to amoxicillin (perhaps due to a β-lactamase producing H. influenzae), switching to cefuroxime axetil or amoxicillin-clavulanate may be appropriate.

    • Acute Bacterial Sinusitis (Oral Cefuroxime Axetil)2,910  

      • Treatment of acute bacterial maxillary sinusitis in adults or adolescents (≥13) caused by susceptible S. pneumoniae or non-β-lactamase-producing H. influenzae.

        • Cefuroxime axetil is indeed used for sinusitis, including in children, especially when organisms like M. catarrhalis or H. flu (which often elaborate β-lactamase) are suspected.

          •  Cefuroxime is effective in this context given its resistance to beta-lactamases associated with these bacteria.

    • Acute Bacterial Exacerbations of Chronic Bronchitis (Oral Cefuroxime Axetil)2,11,12  

      • In adults (and adolescents ≥13), oral cefuroxime is indicated for acute bacterial exacerbations of chronic bronchitis, caused by susceptible strains of S. pneumoniae, H. influenzae (β-lactamase–negative), or H. parainfluenzae.

        • This treatment may be targeted for COPD patients or smokers with chronic bronchitis who get a secondary bacterial infection.

          • Many of those infections involve β-lactamase–producing strains, against which cefuroxime would still be effective (except that some H. influenzae with certain β-lactamases or other resistance may require a stronger agent).

    • Uncomplicated Urinary Tract Infections (Oral Cefuroxime Axetil)2,4,13,14

      • Oral cefuroxime (in patients ≥13) is indicated for uncomplicated UTIs (like simple cystitis) due to E. coli or Klebsiella.

        • Oral cefuroxime is often reserved for cases where first-line oral agents can not be used.

        • Cefuroxime remains an effective oral option for UTIs caused by susceptible organisms, including some that produce narrow-spectrum β-lactamases given that cefuroxime will remain active whereas amoxicillin might not.

    • Uncomplicated Skin and Soft Tissue Infections (Oral Cefuroxime Axetil)2   

      • Oral cefuroxime is indicated in patients ≥13 for uncomplicated skin infections (impetigo, cellulitis) due to MSSA or S. pyogenes.

        • Pediatric impetigo (often staph or strep) can also be treated with cefuroxime suspension as an alternative to first-generation cephalosporins or anti-Staphylococcal penicillins, especially if broader gram-negative coverage is desired to address possible mixed infection.

      • Pathological Classification of uSSTIs
        • Impetigo

          • Impetigo represents the most superficial tier of Uncomplicated Skin and Soft Tissue Infections (uSSTIs, confined strictly to the stratum corneum of the epidermis)

            • Non-bullous Impetigo15 

              • This "honey-crusted" pathology involves the recruitment of neutrophils to the subcorneal space, typically initiated by Staphylococcus aureus or Streptococcus pyogenes.

            • Bullous Impetigo

              • This variant is a toxin-mediated phenomenon. S. aureus produces exfoliative toxin A, which acts as a molecular "scissor" which targets desmoglein 1.16

                • Desmoglein 1 is a cadherin protein responsible for cell-to-cell adhesion in the upper epidermis.

        • Folliculitis, Furuncles, and Carbuncles (Appendage-Based Infections)

          • These infections are associated with the hair follicle unit and progress based on the degree of dermal involvement.

            • Folliculitis

            • Furuncles (Boils) and Carbuncles

              • A furuncle is essentially a deep-seated folliculitis that has evolved into a walled-off abscess involving the dermis.

              • A carbuncle is a more complex pathological entity consisting of several coalescing furuncles that drain through multiple follicular openings.

              • These are mainly caused by S. aureus, and the presence of a carbuncle often signals a greater risk for systemic bacteremia.17

        • Erysipelas (Superficial Dermal & Lymphatic Infection)

          • Erysipelas involves the upper dermis and the superficial lymphatics.

            • Pathology18,19 

              • Erysipelas is characterized by sudden onset, massive dermal edema, and a prominent lymphatic infiltrate.

                • A classic "peau d'orange" (orange peel) texture is caused by the skin's tethering at the hair follicles with significant interstitial swelling.

            • Microbiology

              • Erysipelas is almost exclusively caused by Group A beta-hemolytic Streptococci.

        • Cellulitis (Deep Dermal and Subcutaneous Infection)

          • Cellulitis is associated with deeper dermis and subcutaneous fat.

            • Pathology

              • Unlike erysipelas, the borders of cellulitis are diffuse because the infection spreads along tissue planes in the deeper, less-dense subcutaneous layers.

            • Risk Factors

              • Localized trauma, tinea pedis (serving as a portal of entry), and lymphedema are some risk factors.

              • S. aureus and streptococcus species are implicated in cellulitis

    • Early Lyme Disease  (Oral Cefuroxime Axetil)2

      • Cefuroxime axetil is FDA-approved for early Lyme disease (erythema migrans stage) in adults and children ≥13.21,22

        • Cefuroxime is one of the first-line oral options for Lyme borreliosis caused by Borrelia burgdorferi.

          • Cefuroxime efficacy in this setting is particularly important for patients who cannot take doxycycline notably pregnant women or young children.

            • Doxycycline is contraindicated in pregnancy and in children <8 due to effects on teeth/bone, so cefuroxime is an excellent substitute in those cases.

          • Joint guidelines by the IDSA, American Academy of Neurology, and American College of Radiology identifies cefuroxime as an equivalent alternative to doxycycline or amoxicillin for treating early Lyme disease.2

Section Table of Contents

Site Table of Contents

 
References
  1. MacDougall C Chapter 58 Cell Envelope Disruptors: In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton LL Knollman BC eds) McGraw Hill LLC (2023).

  2. Omole A Awosika A Patel P Cefuroxime. StatPearls. National Library of Medicine. Last update: January 11, 2024. https://www.ncbi.nlm.nih.gov/books/NBK599503/#article-159953.r44#

  3. Gooch WQ Swenson E Higbee M Cocchetto D Evans E Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. https://pubmed.ncbi.nlm.nih.gov/3125976/

  4. Soto C Avdic E  Cefuroxime. John's Hopkins ABX Guide (abstract). Last updated : March 16, 2025. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540105/all/Cefuroxime

  5. Goodch W McLinn S Aronovitz GT Pichichero M Kumar A Kaplan E Ossi M Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streptococcal pharyngitis. Antimicrob agents Chemother. 1993 February;37(2): 159-163. https://pmc.ncbi.nlm.nih.gov/articles/PMC187631/

  6. Syrogiannopoulos G Goumas P Haliotis F Lygatsikas C Spyropoulos C Beratis N Cefuroxime axetil in the treatment of acute otitis media in children. J Chemother. 1992 August;4(4): 221-224. https://pubmed.ncbi.nlm.nih.gov/1403077/

  7. Brook I Use of oral cephalosporins in the treatment of acute otitis media in children. International Journal of Antimicrobial Agents. Volume 24, issue 1, July 2004. 18-23. https://www.sciencedirect.com/science/article/abs/pii/S0924857904000901

  8. Lieberthal A Carroll A Chonmaitree T Ganiats T Hoberman A Jackson M Joffe M Miller D Rosenfeled R Sevilla X Schwartz R Thomas P Tunkel D The Diagnosis and Management of Acute hepatitis Media. Pediatrics (2013) 131 (3): e964-e999. https://publications.aap.org/pediatrics/article/131/3/e964/30912/The-Diagnosis-and-Management-of-Acute-Otitis-Media?autologincheck=redirected

  9. Pakes G Graham J Rauch A Collins J Cefuroxime axetil in the treatment of sinusitis. A review. Arch Fam Med. 1994 February; 3(2): 165-175. https://pubmed.ncbi.nlm.nih.gov/7994439/

  10. Henry D Syndnor Jr A Settipane G Alien J Burroughs S Cobb M Holley Jr H Comparison of cefuroxime axetil in amoxicillin/clavulanate in the treatment of acute bacterial sinusitis. Clinical Therapeutics Volume 21, Issue 7, July 1999, 1158-1170. https://www.sciencedirect.com/science/article/abs/pii/S0149291800800193 .

  11. Langan C Clecner B Cazzola C Bambilla C Holmes C Staley H Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract. 1998 July-August;52(5): 289-297. https://pubmed.ncbi.nlm.nih.gov/9796558/

  12. Cefuroxime Axetil Oral. MedCentral. https://www.medcentral.com/drugs/monograph/3779-384044/cefuroxime-axetil-oral

  13. Leigh D Joy G Tait S Harris K Walsh B Treatment of acute uncomplicated urinary tract infections with single doses of cefuroxime axetil. J Antimicrob Chemother. 1989 February;23(2): 267-273. https://pubmed.ncbi.nlm.nih.gov/2708184/

  14. Cefuroxime (Rx). Doses and uses. Medscape. https://reference.medscape.com/drug/ceftin-zinacef-cefuroxime-342500#0

  15. Nardi N Schaefer T Impetigo. StatPearls. National Library of Medicine. Last Update: July 31, 2023. https://www.ncbi.nlm.nih.gov/books/NBK430974/

  16. Amagai M Matsuyoshi N Wang Z Andl C Stanley J Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Medicine 6 , 1275-1277 (2000). https://www.nature.com/articles/nm1100_1275

  17. Rehmus W Tesini B Furuncles and Carbuncles. June 2023. MSD Manual. (Professional) https://www.msdmanuals.com/professional/dermatologic-disorders/bacterial-skin-infections/furuncles-and-carbuncles

  18. Stevens D Bisno A Chambers H Everett E Dellinger P Goldstein E Gorbach S Hirschmann J Kaplan E Montoya J Wade J Practice Guidelines for the Diagnosis and Management of Skin and-Tissue Infections. Clinical Infectious Diseases Volume 41, Issue 10. November 15, 2005. 1373-1406. https://academic.oup.com/cid/article/41/10/1373/345303

  19. Erysipelas. DermNet. https://dermnetnz.org/topics/erysipelas

  20. Brown B Syed H Watson K Cellulitis. StatPearls. Last Update: December 13, 2025. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK549770/

  21. Nadelman R Luger S Frank E Wisniewski M Collins J Wormser G Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992 August 15;117(4): 273-280. https://pubmed.ncbi.nlm.nih.gov/1637021/

  22. Treatment and Intervention for Lyme Disease. Lyme Disease. CDC . August 16, 2024. https://www.cdc.gov/lyme/treatment/index.html

 

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.